Skip to main
  1. Stocks
  2. AgomAb Therapeutics SA
  3. Forecast
AGMB

AGMB Stock Forecast & Price Target

AGMB Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AgomAb Therapeutics is compelling because ontunisertib has already shown a clean, GI-restricted safety profile in Phase 2a STENOVA, with no cardiac toxicity signal, balanced adverse events versus placebo, and objective signs of anti-fibrotic activity including a 31.8% reduction in non-passable strictures at 200 mg BID. The company also addresses a large unmet need in FSCD, where about ~143K U.S. patients are estimated to be clinically actionable and there are no approved therapies, while the planned 24-week Ph2b NOV-ERA in ~320 patients and the full OLE data in 2H26 offer clear catalysts to validate durability and registrational potential. AGMB’s second asset, AGMB-447, adds upside optionality in IPF, supported by two Phase 1 studies showing lung-restricted exposure, strong ALK5 target engagement, and clean systemic safety, while pro forma cash of approximately €275M supports operations into 1H29.

Bears say

AgomAb Therapeutics is a high-risk clinical-stage biopharmaceutical company with no approved products, making its valuation heavily dependent on early data from ontunisertib and AGMB-447 that may not translate into later clinical success or regulatory approval. Its reliance on a narrow ALK5/TGFβR1 strategy also creates concentration risk, since any safety signal from chronic ALK5 inhibition could impair both lead programs and weaken confidence in the broader pipeline. Financially, about €285M of pro forma cash appears insufficient for sustained development through clinical and preclinical work, raising dilution and financing risk, while reliance on CMOs and competition in FSCD add further execution pressure.

AGMB has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AgomAb Therapeutics SA and is not a guaranteed prediction by Public.com or investment advice.

AGMB Analyst Forecast & Price Prediction

Get the latest AGMB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AGMB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AgomAb Therapeutics SA (AGMB) Forecast

Analysts have given AGMB a Buy based on their latest research and market trends.

According to 6 analysts, AGMB has a Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AgomAb Therapeutics SA (AGMB)


AGMB Analyst Forecast & Price Prediction

Get the latest AGMB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AGMB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AGMB stock data and trends